顺行与逆行入路机械取栓装置治疗急性下肢深静脉血栓
回顾性分析2021年1月至2023年6月接受AngioJet机械取栓治疗的84例急性下肢深静脉血栓患者(88条肢体),比较顺行与逆行入路的疗效。顺行组III级血栓清除率64.8%高于逆行组38.2%(P<0.05),两组3个月静脉通畅率和出血事件无显著差异。作者认为两种入路均安全有效,并推荐放置腔静脉滤器以有效拦截血栓。
要点
- 顺行组III级血栓清除率64.8%(35/54条肢体)高于逆行组38.2%(13/34条肢体),P<0.05。
- 两组3个月静脉通畅率(顺行组96.3% vs 逆行组85.3%)和出血事件(7.4% vs 5.9%)无显著差异(P>0.05)。
- 作者推荐急性下肢深静脉血栓AngioJet取栓后放置腔静脉滤器以有效拦截血栓。
核心结论
- 顺行与逆行入路治疗急性下肢深静脉血栓均安全有效,3个月深静脉通畅率和血栓后综合征发生率无差异。
- 急性下肢深静脉血栓患者AngioJet取栓后血栓脱落风险高,作者推荐放置腔静脉滤器以有效拦截。
研究设计与样本
- 回顾性分析2021年1月至2023年6月接受AngioJet装置治疗的急性下肢深静脉血栓患者临床资料。
- 共84例患者、88条肢体,按手术入路及瓣膜开放方向分为顺行治疗组和逆行治疗组。
主要发现
- 滤器血栓拦截率为35.7%(30例),新发肺栓塞或肺栓塞加重发生率为6.0%(5例),滤器回收率为97.6%(82例)。
- III级血栓清除:顺行组35条(64.8%,占54条肢体的61.4%)vs 逆行组13条(38.2%,占34条肢体的38.6%),P<0.05。
- 3个月静脉通畅:顺行组52条(96.3%)vs 逆行组29条(85.3%),P>0.05;出血事件:顺行组4条(7.4%)vs 逆行组2条(5.9%),P>0.05。
- 顺行组3个月通畅率与血栓清除率[OR=0.546(0.326,0.916)]、血栓形成时间[OR=1.018(1.002,1.036)]及术前血栓评分[OR=1.012(1.002,1.022)]存在统计学显著线性关系。
- 逆行组3个月通畅率与血栓清除率[OR=0.473(0.229,0.977)]存在统计学显著线性关系;顺行组血栓形成时间与静脉临床严重程度评分[0.576(0.467,0.710)]存在统计学显著线性关系。
临床怎么用
- 作者认为顺行与逆行入路均可用于急性下肢深静脉血栓的AngioJet取栓治疗。
- 作者推荐急性下肢深静脉血栓患者AngioJet取栓后放置腔静脉滤器以有效拦截脱落血栓。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To examine the efficacy of antegrade and retrograde approaches with the AngioJet thrombectomy device for the treatment of acute lower limb deep vein thrombosis (DVT) and to evaluate the necessity of filter placement. METHODS: The clinical data of patients with acute lower limb DVT treated with the AngioJet device from January 2021 to June 2023 were retrospectively analyzed. The patients were divided into the antegrade and retrograde treatment groups according to the surgical approach and the direction of valve opening. The thrombosis interception rate of the filter, incidence of pulmonary embolism (PE), thrombectomy effectiveness, venous obstruction rate, and thrombosis recurrence rate of each treatment group were evaluated. In addition, factors affecting patency were analyzed. RESULTS: AngioJet was employed for 84 patients with acute lower limb DVT, treating a total of 88 limbs. The thrombosis interception rate of the filter was 35.7% (30 patients). The incidence of new PE or PE exacerbation was 6.0% (5 patients), and a filter retrieval rate of 97.6% (82 patients) was detected. Thrombus removal of grade III occurred in 35 (64.8%) of the 54 limbs (61.4%) in the antegrade treatment group versus 13 (38.2%) of the 34 limbs (38.6%) in the retrograde treatment group (P < 0.05). At 3 months, venous patency and bleeding events involved 52 (96.3%) and 4 (7.4%) limbs in the antegrade treatment group, respectively, versus 29 (85.3%) and 2 (5.9%) in the retrograde treatment group, respectively (P > 0.05). Regression analysis was performed to determine factors that may affect 3-month patency in both groups. Statistically significant linear relationships were found between 3-month patency and thrombus removal rate [odds ratio [OR] = 0.546 (0.326, 0.916)], thrombus formation time [OR = 1.018 (1.002, 1.036)], and preoperative thrombosis score [OR = 1.012 (1.002, 1.022)] in the antegrade treatment group, as well as thrombus removal rate [0.473 (0.229, 0.977)] in the retrograde treatment group. In regression analysis of factors affecting patency in both groups and the venous clinical severity score/Villalta score, a statistically significant linear relationship was found between thrombus formation time and the venous clinical severity score in the antegrade treatment group [0.576 (0.467, 0.710)]. CONCLUSIONS: Both antegrade and retrograde approaches are safe and effective for the treatment of acute lower limb DVT. There are no differences in 3-month deep vein patency and post-thrombotic syndrome (PTS) incidence rates. Individuals with acute lower limb DVT are at high risk of thrombus shedding after treatment with AngioJet thrombectomy, and placement of a vena cava filter (VCF) is recommended for effective interception.
引用
- Xuan T, Jianlong L, Jinyong L, et al. Antegrade and Retrograde Approaches with a Mechanical Thrombectomy Device for the Treatment of Acute Lower Limb Deep Vein Thrombosis. Ann Vasc Surg. 2024. PMID: 38942376. doi:10.1016/j.avsg.2024.04.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。